| 2 min read
Register for free to listen to this article
Listen with Speechify
0:00
2:00
PRINCETON, N.J.—Rosetta Genomics Ltd. and Moffitt Cancer Center have begun a strategic alliance for the discovery, development and commercialization of a number of microRNA-based cancer diagnostics. The alliance will run for three years, with Rosetta providing funding for projects initiated by Moffitt investigators that parallel Rosetta’s strategic priorities. No financial details for the agreement were provided.
 
“We are excited about the opportunity to develop novel cancer diagnostics for important, unmet medical needs based on our proprietary microRNA platform technologies with Moffitt’s world-class team of oncologists and pathologists who have dedicated their careers to advancing cancer patient care,” Kenneth A. Berlin, president and CEO of Rosetta Genomics, commented in a statement. “New molecularly targeted therapies continue to drive the need for more accurate classification of tumor types, which helps to guide treatment decisions, monitor therapy, predict outcomes and more. Responding to these unmet medical needs, the overall purpose of this alliance is to advance the care of cancer patients through the development of diagnostic assays based on Rosetta’s microRNA technology, which, with its high reproducibility, robustness and accuracy, is well suited to provide this valuable clinical information.”
 
Rosetta brings with it a proprietary discovery microarray platform with more than 2,500 human microRNAs, as well as its proprietary RT-PCR platform, while Moffitt provides research expertise and a team made up of medical oncologists, pathologists and researchers in clinical and translational research.
 
“Moffitt is committed to bringing innovative oncology diagnostics to patients in order to optimize clinical outcomes. This goal is particularly well aligned with Rosetta’s expertise, and we are pleased to partner with a known leader in microRNA technology,” said Anthony Magliocco, M.D., chair of the Anatomical Pathology Program and executive director of the Morsani Molecular Diagnostics Laboratory at Moffitt. “We look forward to working with the Rosetta team on research collaborations for the development of new, effective diagnostic assays and novel tests. This alliance should produce cutting-edge research and data that can be the subject of scientific publications and presentations. Importantly, the development of such tests will benefit patients, who are the ultimate focus of our work at Moffitt.”
 
This is the second agreement for the two organizations so far this year. In June, Moffitt and Rosetta announced that they would be working together to advance the development and commercialization of Rosetta’s thyroid neoplasia assay. Per the agreement, Rosetta will be working with Marino Leon, M.D., an associate member of Moffitt’s Department of Anatomic Pathology. Financial details were not disclosed.
 
 
SOURCE: Rosetta Genomics press release

About the Author

Related Topics

Loading Next Article...
Loading Next Article...
Subscribe to Newsletter

Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

Subscribe

Sponsored

Clear sample tubes are shown in a clear tote with red lids in a sample prep robot with a blue and silver industrial lab background.

The crucial role of sample preparation in biotherapy manufacturing

Discover how better sample preparation can unlock improved assay accuracy and analytical results.
A black mosquito is shown on pink human skin against a blurred green backdrop.

Discovering deeper insights into malaria research

Malaria continues to drive urgent research worldwide, with new therapies and tools emerging to combat the parasite’s complex lifecycle and global burden.
Three burgundy round and linear conformations of oligonucleotides are shown against a black background.

Accelerating RNA therapeutic testing with liver microphysiological platforms

Researchers can now study oligonucleotide delivery and efficacy in a system that models a real human liver.
Drug Discovery News March 2025 Issue
Latest IssueVolume 21 • Issue 1 • March 2025

March 2025

March 2025 Issue

Explore this issue